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fractionated EBRT for prostate cancer: comparison
of PSA slope and nadir
Mekhail Anwar*, Vivian Weinberg, Albert J Chang, I-Chow Hsu, Mack Roach III and Alexander GottschalkAbstract
Background: Patients with early stage prostate cancer have a variety of curative radiotherapy options, including
conventionally-fractionated external beam radiotherapy (CF-EBRT) and hypofractionated stereotactic body radiotherapy
(SBRT). Although results of CF-EBRT are well known, the use of SBRT for prostate cancer is a more recent development,
and long-term follow-up is not yet available. However, rapid post-treatment PSA decline and low PSA nadir have been
linked to improved clinical outcomes. The purpose of this study was to compare the PSA kinetics between CF-EBRT
and SBRT in newly diagnosed localized prostate cancer.
Materials/methods: 75 patients with low to low-intermediate risk prostate cancer (T1-T2; GS 3 + 3, PSA < 20 or
3 + 4, PSA < 15) treated without hormones with CF-EBRT (>70.2 Gy, <76 Gy) to the prostate only, were identified
from a prospectively collected cohort of patients treated at the University of California, San Francisco (1997–2012).
Patients were excluded if they failed therapy by the Phoenix definition or had less than 1 year of follow-up or <3
PSAs. 43 patients who were treated with SBRT to the prostate to 38 Gy in 4 daily fractions also met the same
criteria. PSA nadir and rate of change in PSA over time (slope) were calculated from the completion of RT to 1, 2
and 3 years post-RT.
Results: The median PSA nadir and slope for CF-EBRT was 1.00, 0.72 and 0.60 ng/ml and -0.09, -0.04, -0.02 ng/ml/
month, respectively, for durations of 1, 2 and 3 years post RT. Similarly, for SBRT, the median PSA nadirs and slopes
were 0.70, 0.40, 0.24 ng and -0.09, -0.06, -0.05 ng/ml/month, respectively. The PSA slope for SBRT was greater than
CF-EBRT (p < 0.05) at 2 and 3 years following RT, although similar during the first year. Similarly, PSA nadir was
significantly lower for SBRT when compared to EBRT for years 2 and 3 (p < 0.005).
Conclusion: Patients treated with SBRT experienced a lower PSA nadir and greater rate of decline in PSA 2 and
3 years following completion of RT than with CF-EBRT, consistent with delivery of a higher bioequivalent dose.
Although follow-up for SBRT is limited, the improved PSA kinetics over CF-EBRT are promising for improved
biochemical control.
Keywords: SBRT, Stereotactic body radiotherapy, Prostate, External beam, Conventionally fractionated, Nadir,
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Patients with early stage prostate adenocarcinoma face a
challenge in selecting from a variety of curative radio-
therapy options, ranging from conventionally fractionated
external beam radiotherapy (CF-EBRT), taking weeks, to
single session brachytherapy implants. Increasingly, con-
formal radiation delivery techniques have safely escalated
the dose to the prostate by either increasing the number
of daily fractions [1-3] or adding a boost [4-7]. These ap-
proaches increase the delivered bioequivalent dose (BED),
and consequently the biochemical control rate, but are as-
sociated with additional treatment time or, in the case of a
brachytherapy boost, an invasive procedure.
The desire to deliver a higher bioequivalent dose
(BED) to the prostate in fewer treatments prompted the
investigation of hypofractionation, whereby the dose per
fraction is increased while the total number of fractions
is decreased. This strategy coupled well with reports of a
low α/β ratio [8] (Table 1) for prostate cancer. Moreover,
the reported α/β ratio values for prostate adenocarcin-
oma are consistently less than 3, indicating that prostate
adenocarcinoma is a slow growing cancer with a greater
ability to repair damage between fractions [9]. This im-
plies that hypofractionated radiotherapy should have an
increased biologic effect over standard fractionation. A
review of hypofractionation trials demonstrated an in-
creasing biochemical control rate with increasing BED,
assuming an α/β of 1.5 [9].
These observations led to use of high dose rate bra-
chytherapy (HDR), first as a boost [17-19], and then as
definitive monotherapy [20-23]. Due to its superior con-
formality, HDR could deliver high bioequivalent doses
while sparing neighboring critical structures. Although
these studies leveraged hypofractionation, some patients
are not operative candidates for HDR or wish to avoid an
invasive procedure. More recently, the advent of image
guided stereotactic body radiotherapy (SBRT) has allowed
the precise delivery of highly conformal radiotherapy,Table 1 Summary of α/β values
Ref α/β (Gy) 95% Confidence interval
Brenner and Hall [8] 1.5 [0.8,2.2]
Arcangeli 2010 −0.45 [−1.31, 0.41]*
Leborgne 2011[10] 1.86 [0.7, 5.1]
Lukka 2005[11] 2.02 [−1.03, 5.07]*
Valdagni 2005 7.44 [−13.97, 28.86]*
Yeoh 2011[12] 0.13 [−1.06, 1.31]*
Vogelius 2013 [13] −0.07 [−0.73 – 0.59]
Williams 2007 [14] 2.6 [0.9, 4.8]
Fowler 2001 [15] 1.49 [1.25, 1.76]
Brenner 2002 [16] 1.2 [0.03, 4.1]
(*Taken from Vogelius et al. [13]).enabling a high dose to be delivered to a target, while
sparing nearby normal tissue, something previously only
achievable with brachytherapy. Therefore, we have rep-
licated the dosimetry of HDR (38 Gy in 4 fractions)
using Stereotactic Body Radiotherapy (SBRT) [24], in
effect emulating HDR via a non-invasive external beam
approach.
Feasibility results for the use of hypofractionated SBRT
in prostate cancer have been reported by our group [25],
as well as others [26-28]. These early results are promi-
sing, though the application of SBRT for prostate adeno-
carcinoma is too recent a development to allow long
term comparisons of efficacy with established treatment
methods. However, the prevalence of this disease com-
bined with the myriad of treatment options motivates
further comparisons based on what data are currently
available.
Prostate cancer is unique in that a well-established
biomarker, prostate specific antigen (PSA), is available
for monitoring response to treatment. In patients whose
PSA level is not confounded by androgen deprivation
therapy, analysis of PSA kinetics after treatment could
reveal the biological effect of radiation on prostate can-
cer and potentially reflect clinical outcome. Lower PSA
nadir and rapid decline in PSA after treatment have been
related to improved clinical outcome. Specifically, a
lower PSA nadir (< 0.5 ng/ml) has been associated with
increased freedom from biochemical failure [29-32].
While increasing PSA values can either indicate bio-
chemical failure [33] or PSA bounce [34], continued
decline or stability in PSA is linked with biochemical
control [35,36]. The interpretation of the PSA rate of de-
cline following radiotherapy, as measured by the PSA
slope, is more controversial. Some studies have shown a
relationship between the magnitude of the PSA slope
and clinical outcomes [35,37], while other studies have
not [38-40]. Regardless, the rate of PSA decline is re-
flective of the cellular response to radiation. Theore-
tically, in patients whose PSA level is not confounded by
the use of hormones or adenocarcinoma outside the ra-
diation field, the study of PSA kinetics after treatment
could yield information about the biological effect of
radiation on prostate cancer and, potentially, clinical
outcome.
We seek to gain insight into the potential long term
clinical outcomes of SBRT for prostate cancer by com-
paring PSA kinetics (nadir and slope) in patients treated
with SBRT with those of patients treated with CF-EBRT.
Because the two modalities use the same method of de-
livering ionizing radiation, 6 MV photons, the major dif-
ferences between the cohorts are the fraction size and
total dose. Our hypothesis is that, due to the low re-
ported α/β ratio for prostate cancer, the hypofractio-
nated regimen delivered with SBRT, should produce a
Table 2 Patient baseline characteristics
CK EBRT
# Evaluable patients
Total 43 75
# Follow up from end of RT
Thru Year 1 43 42
Thru Year 2 38 62
Thru Year 3 27 68
# with PSA follow-up for all 3 intervals 26 37
Median age at RT (yrs) (range) 69.0 (51 – 83) 69.8 (55 – 82)
Gleason score:
3 + 3 24 (56%) 59 (79%)
3 + 4 19 (44%) 16 (21%)
Pretreatment PSA (ng/mL)
Median (range) 6.2 (2.0 – 13.5) 5.9 (0.1 – 16.7)
# >10.0 ng/mL 10 (23%) 19 (25%)
Years of RT 2006 – 2011 1997 – 2006
Median follow-up (mos.) (range) 29.3 (12 – 75) 62.1 (15 – 156)
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flected in a greater rate of PSA decline and a lower PSA
nadir.
Patients and methods
Patient selection
This single institution retrospective study was approved
by our Committee on Human Research with a waiver of
informed consent and was complaint with the Health
Insurance Portability and Accountability Act.
Patients with biopsy proven prostate adenocarcinoma
were seen in a multidisciplinary clinic and counseled on
treatment options, including surgery and radiotherapy.
Patients classified as low to low-intermediate risk (T1-T2
with GS 3 + 3, PSA < 20 or GS 3 + 4, PSA < 15) were
eligible for treatment with radiation to the prostate and
seminal vesicles only, without androgen deprivation therapy
(ADT). Treatment was selected by the patient and phys-
ician. At the time of this analysis, of the options available,
including permanent prostate implant (PPI), high dose rate
brachytherapy, CF-EBRT with intensity modulated radia-
tion therapy (IMRT) and SBRT, 71 patients have been
treated with SBRT using the Cyberknife robotic radiosur-
gery/SBRT system (Accuray Incorporated, Sunnyvale, CA).
In order to accurately assess PSA kinetics in response to
radiotherapy, patients were excluded if they failed therapy
by the Phoenix definition [33], received pelvic radiotherapy,
or had their PSA levels suppressed by the use of hormones.
This was done to insure a uniform population in which to
evaluate PSA outcomes. All included patients had at least 1
year of follow-up, and 3 serial PSAs. Patients were followed
by ultrasensitive PSA assay, and results below the detection
limit of the assay (for example < 0.1 ng/ml) were entered as
the respective detection limit (for example 0.1 ng/ml for a
value of < 0.1 ng/ml) for the purposes of data analysis. A
PSA bounce was determined when the PSA value at follow-
up increased over the previous nadir by > 0.2 ng/mL but
subsequently steadily decreased with follow-up. Of the 71
eligible patients, 43 patients met these criteria. To identify
the cohort of patients treated with CF-EBRT, the records
from a prospectively collected cohort of patients treated at
UCSF from 1997 through 2006 were reviewed. We identi-
fied 75 patients treated with standard fractionated EBRT
who met the above inclusion criteria. Since the vast ma-
jority of patients treated with CF-EBRT alone received
doses between 70.2 Gy and 76 Gy, we excluded patients
who received doses above and below this interval in order
to have a homogenous dose response in this group of pa-
tients. A comparison between the two radiotherapy cohorts
of patient baseline characteristics is shown in Table 2.
SBRT technique
The specifics of the SBRT technique have been described
previously [25], but briefly, the dose and fractionation arebased on the UCSF HDR monotherapy experience, with
38 Gy in 4 fractions of 9.5 Gy to an isodose of approxi-
mately 60-80% and a 2 mm expansion for patient setup
and motion. Prior to treatment, 3 fiducial markers were
inserted into the prostate, enabling real-time tracking of
and automatic beam adjustment for intrafraction prostate
motion. No patients were treated with hormone therapy
or pelvic radiotherapy.
Statistical analysis
Because the use of SBRT for prostate adenocarcinoma is
a relatively new application, significantly longer follow-
up exists for patients treated with CF-EBRT as opposed
to SBRT, preventing direct comparison of clinical out-
comes. To eliminate the effect of differing follow-up
durations between the groups, we calculated the PSA
nadir and rate of change in PSA over an interval of time
from the completion of radiotherapy (RT) to 1, 2, and
3 years post-treatment with the requirement of at least
3 PSA measurements recorded for each estimate. It
might mean that a patient has only 2 measurements du-
ring years 1 and 2 after radiotherapy so this patient
would be evaluated for the two year interval with the
slope and PSA nadir determined from 4 values. Of the
eligible patients, 37 and 26 patients treated with EBRT
and SBRT, respectively, had increasing PSA follow-up
over the 3 years with a sufficient number of measure-
ments to calculate the slope and determine the PSA
nadir for each of the three intervals.
To summarize the PSA measurements the slope, the
rate of change of PSA over time, with units of ng/ml/
month, the PSA nadir and time to PSA nadir were
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tive statistics (e.g. mean, median, range) were tabulated
for patient, disease and PSA parameters for each RT co-
hort. A t test was performed to compare mean values,
the Mann–Whitney test was used to compare distri-
butions and the log rank test was calculated to compare
the distributions of time to PSA nadir between the two
RT subsets. There was no adjustment for multiple com-
parisons and statistical significance was defined as a
probability value less than 0.05. Analyses were per-
formed using Statistica v6.0 (StatSoft, Inc, Tulsa, OK).
Results
To investigate PSA kinetics after radiotherapy, the slope
and nadir of the PSA outcome after radiotherapy was cal-
culated for each radiotherapy cohort for 3 intervals follo-
wing radiotherapy (0 to 1 year, 0 to 2 years, and 0 to
3 years, Table 3). Figure 1 is an illustrative example for a
single patient treated with SBRT with serial PSA values
declining over time, with the rate of change in PSA since
radiotherapy summarized by the slope for each of the
3 time intervals. The rate of PSA decline (slope) for the
CF-EBRT cohort was maximal in the first year, but tapered
off quickly in the following years, with median valuesTable 3 Results (all patients)
Through year
PSA Measurements #
Mean (range) 1
2
3
Nadir PSA (ng/mL)
Median (range) 1
2
3
Time to Nadir PSA (mos.)
Median (range) 1
2
3
Rate of PSA change: ng/mL/month
Median slope (range) 1 −
2 −
3 −
SBRT: Stereotactic Body Radiotherapy.
CF-EBRT: Conventionally fractionated external beam radiotherapy.
p: Statistical significance.
# The t test was performed to compare the mean number of PSA measurements be
summarize the results.
^ The log rank test was used due to compare the time to nadir PSA distributions b
to summarize the results.
* The Mann–Whitney test was performed to compare the PSA nadir and slope distr
summarize the results.of -0.09, -0.04, -0.02 ng/ml/month for durations of 1, 2
and 3 years post RT, respectively. Consistent with a slower
rate of decline in years 2 and 3 for this cohort, the PSA
nadir did not continue to substantially drop after year 2,
going from a median of 1.00 ng to 0.72 ng to 0.60 ng for
durations of 1, 2 and 3 years post RT, respectively.
Although the magnitude of the slopes for both SBRT and
CF-EBRT decreased with time, there was a greater pro-
longed rate of decline with SBRT. While the distribution
of the slope for SBRT initially did not differ from the
CF-EBRT group in year 1 (medians: -0.09 ng/ml/month
for both groups), the distributions were significantly dif-
ferent with a greater median rate of change for 2 and
3 years post-RT (−0.06 and −0.05 ng/ml/month, respec-
tively for SBRT versus (−0.04 and −0.04 ng/ml/month for
CF-EBRT). This trend was also seen when analysis was
limited to those patients with 3 years of follow up,
although it was no longer statistically significant in this re-
duced patient population. The steeper rate of PSA decline
for SBRT resulted in lower median PSA nadirs of 0.70,
0.40, and 0.24 ng for durations of 1, 2 and 3 years post RT
which was statistically significantly lower for years 2 and 3
(p ≤ 0.002). Achieving a significantly lower PSA nadir 2
and 3 years after RT was also observed when limited toSBRT CF-EBRT p-value
3.9 (2 – 6) 4.1 (3 – 11)
5.8 (4 – 9) 5.6 (3 – 15)
7.6 (5 – 11) 7.3 (3 – 21)
0.70 (0 – 2.5) 1.00 (0 – 8.5)
0.40 (0 – 1.4) 0.72 (0 – 2.7) p = 0.0005*
0.24 (0.1 – 1.4) 0.60 (0 – 2.2) p = 0.002*
12.0 (2.7 – 15.0) 11.5 (1.2 – 15.0)
21.0 (2.7 – 26.9) 18.0 (1.2 – 26.9)
32.3 (2.7 – 41.6) 28.6 (1.0 – 41.1) p = 0.004^
0.09 (−0.88, 0.04) −0.09 (−0.60, 0.06)
0.06 (−0.38, 0.01) −0.04 (−0.65, 0.05) p = 0.04*
0.05 (−0.19, 0.00) −0.02 (−0.38, 0.04) p = 0.006*
tween the two groups for each interval with means and ranges presented to
etween the two groups for each interval with medians and ranges presented
ibutions between the two groups with medians and ranges presented to
Table 4 Results (Patients with continuous PSA follow up in al
Through year
# Evaluable patients with PSA
Follow-up for All 3 intervals
PSA measurements
Mean (range) 1
2
3
Nadir PSA (ng/mL)
Median (range) 1
2
3
Time to Nadir PSA (mos.)
Median (range) 1
2
3
Rate of PSA change: ng/mL/month
Median slope (range) 1
2
3
SBRT: Stereotactic Body Radiotherapy.
CF-EBRT: Conventionally fractionated external beam radiotherapy.
p: Statistical significance.
# The t test was performed to compare the mean number of PSA measurements be
summarize the results.
^ The log rank test was used due to compare the time to nadir PSA distributions b
to summarize the results.
* The Mann–Whitney test was performed to compare the PSA nadir and slope distr
summarize the results.
Figure 1 Calculation of slope and PSA nadir for a sample
patient for 3 time durations, 1, 2 and 3 years post-RT for a
patient treated with SBRT.
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(p ≤ 0.02, Table 4). Consistent with a lower PSA nadir for
SBRT, the time to PSA nadir was statistically longer
for SBRT when compared to CF-EBRT over 3 years
(p < 0.005). The incidence of PSA bounce was more fre-
quent in patients treated with either SBRT (5 patients,
12%) compared to CF-EBRT (7 patients, 9%), but the
small number of instances prevents determination of stat-
istical significance.
Although the inclusion criteria make this a relatively
homogenous population and subsets for comparison of
the PSA kinetics were small, the analysis by Gleason
score shows that SBRT results in a lower PSA nadir re-
gardless of Gleason score (3 + 3 versus 3 + 4, Table 5).
Furthermore, these trends held constant when analyzed
by age (Table 5) or pre-treatment PSA (Table 6).
Discussion
SBRT delivered in 4 fractions of 9.5 Gy has a BED of
218 Gy, assuming an α/β of 2 (e.g. BED2), compared with
a BED2 of 140–150 Gy with CF-EBRT given in 35–38
fractions of 2 Gy. Consistent with dose escalation trialsl 3 intervals)
SBRT CF-EBRT p-value
26 37
3.8 (2 – 5) 4.2 (3 – 11)
5.8 (4 – 8) 6.6 (4 – 15)
7.6 (5 – 11) 9.0 (6 – 21) p = 0.03#
0.81 (0.1 – 2.5) 1.00 (0 – 8.5)
0.45 (0.1 – 1.4) 0.86 (0 – 2.5) p = 0.02*
0.25 (0.1 – 1.4) 0.70 (0 – 2.2) p = 0.002*
12.0 (2.7 – 15.0) 11.5 (1.2 – 15.0)
22.1 (2.7 – 26.9) 17.9 (1.2 – 26.9)
31.5 (2.7 – 41.6) 27.4 (1.2 – 41.0) p = 0.02^
−0.08 (−0.88, 0.04) −0.09 (−0.60, 0.06)
−0.06 (−0.38, 0.004) −0.04 (−0.65, 0.05)
−0.05 (−0.19, 0.001) −0.03 (−0.38, 0.02)
tween the two groups for each interval with means and ranges presented to
etween the two groups for each interval with medians and ranges presented
ibutions between the two groups with medians and ranges presented to
Table 5 Comparison of PSA kinetics between CK and CF-EBRT by Gleason score and age subsets: probability values
Gleason score 3 + 3 Gleason score 3 + 4
Through year:
Nadir PSA (ng/mL)
1 ns ns
p = 0.01 p = 0.03
p = 0.03 p = 0.02
Time to Nadir PSA (mos.)
1 ns ns
2 ns ns
3 p = 0.02 ns
Rate of PSA change: ng/mL/month
1 ns ns
2 p = 0.02 ns
3 p = 0.01 ns
Age < 70 Age ≥ 70
Nadir PSA (ng/mL)
1 ns ns
2 p = 0.002 p = 0.03
3 p = 0.01 ns
Time to Nadir PSA (mos.)
1 ns ns
2 ns ns
3 p = 0.004 ns
Rate of PSA change: ng/mL/Month
1 ns ns
2 ns ns
3 (p = 0.09) p = 0.03
For each Gleason score subset (3 + 3 vs 3 + 4) and age subset (<70 vs ≥70) the PSA outcomes were compared between SBRT and CF-EBRT. The distributions for
PSA nadir and PSA slope were compared using the Mann–Whitney test. The distributions for the time to PSA nadir was compared using the log rank test.
[ns: not significant].
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ber of fractions [30,41,42] (and consequently increased
BED), we expect the hypofractionated SBRT regimen to
produce a lower PSA nadir as well as a greater rate of
decline in PSA over the same time period, than CF-EBRT.
Several reports have shown PSA kinetics after CF-EBRT
to follow an exponential decay, with half-lives varying
from 0.27 to 0.67 years [35,43,44], indicating that the ma-
jority of the PSA decline occurs in the first year, consistent
with our results. Although both modalities have similar
PSA slopes through year 1, the rate of PSA decline for
patients treated with CF-EBRT substantially falls off, and
approaches 0 at year 3. The rate of decline for those
treated with SBRT does not fall off as quickly, and the rate
of decline at 3 years is still notable. Although this cannot
be used to derive clinical outcomes, it is clear that the
hypofractionated regimen has a distinct effect on the pros-
tate cancer cells which produce the predominance of thePSA. More importantly, the PSA nadirs for SBRT are sta-
tistically significantly lower than CF-EBRT for years 2 and
3, regardless of whether all eligible patients, or only those
with long term follow up post-RT, are analyzed, consistent
with delivery of a greater BED. Our findings are consistent
with the trends reported by other investigators, with
Zelefksy et al. [45] showing a PSA nadir of 0.6 ng/ml at
23 months with 81 Gy CF-EBRT, while Katz et al. [46]
showed a longer, continued drop in PSA resulting in a
PSA dropping to 0.12 ng/ml with patients treated with
SBRT. Additionally, a pooled analysis of SBRT patients
[47] further supported a trend with a more rapid drop in
PSA, reporting a median PSA of 0.2 ng/ml at 3 years.
This study has several limitations. As previously noted,
due to the large difference in follow-up between the
SBRT and CF-EBRT study populations, overall PSA nadir
could not be directly compared. Therefore, we analyzed
the PSA nadir and slope in identical time intervals from
Table 6 Comparison of PSA kinetics between SBRT and CF-EBRT by pre-treatment PSA (probability values)
Pretreatment PSA (ng/mL)
≤10 >10 >4
Through year
Nadir PSA (ng/mL)
1 ns ns ns
2 p = 0.001 ns p = 0.002
3 p = 0.005 ns p = 0.001
Time to Nadir PSA (mos.)
1 ns ns ns
2 ns ns ns
3 p = 0.04 p = 0.03 p = 0.01
Rate of PSA change: ng/mL/Month
1 ns ns ns
2 p = 0.05 ns (p = 0.08)
3 (p = 0.06) ns p = 0.02
For each of the 3 pretreatment PSA subsets the PSA outcomes were compared between SBRT and CF-EBRT. The distributions for PSA nadir and PSA slope were
compared using the Mann–Whitney test. The distributions for the time to PSA nadir was compared using the log rank test.
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different follow up periods. Although prostate adeno-
carcinoma treated with CF-EBRT is known to reach its
nadir in 2–3 years, the time to nadir is unknown for
SBRT. Therefore, the median nadir during 3 years post
RT of 0.24 ng/mL may not represent the true PSA nadir.
In fact, the significant difference in the distributions of
the slope which is still present through years two and
three may indicate the occurrence of a lower PSA nadir
with increased follow-up. The significantly lower PSA
nadir for SBRT versus CF-EBRT is also reflected in the
longer time to nadir for SBRT. Continued follow-up will
allow for additional monitoring of PSA slope and nadir
in SBRT patients and to investigate these trends. Ad-
ditionally, in order to accurately compare the PSA kine-
tics, patients who failed by the Phoenix definition were
excluded. Patients with a rising PSA after treatment may
represent those with microscopic foci of prostate adeno-
carcinoma outside the prostate or those with high grade
disease not adequately represented in the biopsy.
The majority of the included patients receiving CF-
EBRT here were treated in the pre-dose escalation era,
and received between 70.2 and 76 Gy. This represents
only an 8% difference in BED2 from a dose of 78 Gy, so
while these lower prescription doses may decrease both
the magnitude of the PSA slope and nadir for this group
of patients, the effect should not be significant when com-
pared to modern doses. Although the inclusion criteria
were limited to patients with low to low-intermediate risk
prostate adenocarcinoma, differences in Gleason score
and pre-treatment PSA may represent variations in the
underlying biology of the prostate adenocarcinoma, and
therefore affect the response to radiation. To address this,a comparison between the RT cohorts in PSA kinetics
within subsets was performed, and patients treated with
SBRT had lower PSA nadir regardless of Gleason score,
pre-treatment PSA (≤10, >4), or age < 70.
Conclusion
Delivery of increased BED in standard fractionation has
been associated with lower PSA nadir and improved bio-
chemical outcome in patients treated for prostate adeno-
carcinoma. Studies of the α/β ratio for prostate cancer
point to a low value that would benefit from hypofrac-
tionated treatment. Not only should a hypofractionated
regimen provide increased BED and biochemical control,
the need for far fewer fractions means a dramatically de-
creased treatment time for the patient. Existing studies
using high dose rate brachytherapy as monotherapy for
low and low-intermediate risk patients have demon-
strated success, confirming this approach, but require an
invasive procedure. To leverage the benefits of hypofrac-
tionation while still utilizing external beam radiotherapy,
at UCSF we have been treating low and low intermediate
risk prostate cancer patients with SBRT in a dose and
fractionation scheme modeled from the HDR expe-
rience, 9.5 Gy for 4 fractions, providing a BED2 of
218 Gy. We hypothesized that the greater BED delivered
by SBRT would result in improved kinetics (consistently
greater rate of PSA decline over time and lower PSA
nadir). The data presented here support this, with lower
PSA nadirs as well as a steeper decline in PSA from
SBRT greater in years 2 and 3 after treatment than with
CF-EBRT. These findings are consistent with the notion
of a low α/β for prostate cancer and significantly in-
creased BED with hypofractionation. Although follow-up
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the clinic, the improved PSA kinetics of SBRT over CF-
EBRT are promising for improved biochemical control.
Abbreviations
SBRT: Stereotactic body radiotherapy; CF-EBRT: Conventionally fractionated
external beam radiotherapy.
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